[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"functional-constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:functional-constipation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,66,97,120,147,184,215,248,270],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053251","core-based-movement-and-nutritional-counselling-for-stress-and-metabolic-outcomes-in-overweight-women-with-functional-constipation-100053251",false,"NCT07694830","Core-Based Movement and Nutritional Counselling for Stress and Metabolic Outcomes in Overweight Women With Functional Constipation","Effects of Core-Based Movement and Nutritional Counselling on Stress, Cortisol, and Lipid Profiles in Overweight Women With Functional Constipation","Inclusion Criteria:\n\n* Female participants diagnosed with functional constipation according to Rome IV diagnostic criteria.\n* Age between 18 and 45 years.\n* Body mass index between 25 and 29.9 kg\u002Fm².\n* Ability to participate safely in the core-based movement exercise program.\n* Willingness to follow the nutritional counselling program and study procedures.\n\nExclusion Criteria:\n\n* Participants will be excluded if they have any organic gastrointestinal disorder or any disease that may affect gastrointestinal transit or colonic function.\n* Participants with inflammatory bowel disease, concurrent infectious enteritis, malignant tumors, or a history of gastrointestinal surgery, including resection of the stomach, small intestine, or large intestine, will be excluded.\n* Participants receiving steroids, antibiotics, immunosuppressive medications, or routinely using laxatives will be excluded.\n* Participants with hyperthyroidism, hypothyroidism, or other endocrine or metabolic disorders that may affect gastrointestinal function will be excluded.\n* Participants with serious cardiovascular, respiratory, renal, hepatic, hematological, neurological, or psychiatric disorders will be excluded.\n* Participants with a history or current evidence of alcohol abuse within the previous year will be excluded.\n* Participants currently engaged in an intense workout regimen will be excluded.\n* Participants with a musculoskeletal disability that may interfere with exercise applicability, such as cervical or lumbar radiculopathy, will be excluded.","FEMALE","18 Years","45 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will investigate the effect of core-based movement and nutritional counselling on stress, serum cortisol, and lipid profile in overweight women with functional constipation.\n\nSixty overweight women with functional constipation will be randomly assigned into two equal groups. The study group will include 30 participants who will receive a core-based movement exercise program for 8 weeks, two sessions per week, in addition to guideline-based nutritional counselling. The control group will include 30 participants who will receive guideline-based nutritional counselling only for 8 weeks.\n\nThe outcomes will include perceived stress, serum cortisol level, lipid profile, stool form, sleep quality, and quality of life.",[27],"Functional Constipation","NOT_YET_RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":21},"2026-08-25",{"date":36,"type":21},"2027-03-30",{"name":38,"class":39},"Cairo University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100631997","probiotics-for-constipation-relief-in-adults-100631997","NCT07507955","Probiotics for Constipation Relief in Adults","To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Adults aged 18-65 years;\n2. Individuals diagnosed with constipation, defined as fewer than 3 bowel movements per week and\u002For Bristol Stool Form Scale (BSFS) types 1-2;\n3. Able and willing to comply with all study procedures and complete the study;\n4. Provided written informed consent prior to participation;\n5. Participants (including males) must have no intention of conception from 14 days before screening until 6 months after study completion and agree to use effective contraception.\n\nExclusion Criteria:\n\n1. Recent use of products with similar effects that may interfere with study outcomes; Significant dietary changes during the study period;\n2. History of severe allergy or immunodeficiency;\n3. Pregnant or breastfeeding women, or those planning pregnancy;\n4. Presence of serious systemic diseases (e.g., cardiovascular, pulmonary, hepatic, renal, endocrine, or malignant conditions);\n5. Use of antibiotics within the past 2 weeks;\n6. Individuals with severe psychiatric or neurological disorders;\n7. Poor compliance, including failure to take the study product or attend scheduled visits;\n8. Any other condition deemed unsuitable by the investigator.",true,"ALL","65 Years",{"count":52,"type":21},105,[24],"This study aims to evaluate the efficacy and safety of Bifidobacterium animalis subsp. lactis BLa36 in adults with functional constipation. In this randomized, double-blind, placebo-controlled trial, participants will receive BLa36 supplementation or placebo for 8 weeks. Clinical outcomes will be assessed using validated gastrointestinal symptom scales, stool characteristics, and quality-of-life measures. In addition, changes in inflammatory and immune markers, gut microbiota composition, metabolic indicators, and gut-brain axis-related parameters will be evaluated to comprehensively determine the effects of BLa36 on intestinal function and overall health.",[27],"2026-06-05",{"date":58,"type":32},"2026-06-09",{"date":60,"type":21},"2026-06-10",{"date":62,"type":21},"2027-01-20",{"name":64,"class":65},"Wecare Probiotics Co., Ltd.","INDUSTRY",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100599945","a-study-of-herbal-supplements-in-cancer-survivors-with-constipation-100599945","NCT07091084","A Study of Herbal Supplements in Cancer Survivors With Constipation","Herbal Formula Ma-Zi-Ren-Wan (MZRW) on Bowel Movement Function and Gut Microbiome Among Cancer Survivors With Constipation: A Double-blinded Randomized Controlled Trial (RELIEVE)","Inclusion Criteria:\n\n* Age 18 years or greater;\n* A diagnosis of cancer with no restrictions placed on type of cancer or stage;\n* Completed surgery, chemotherapy, immunotherapy, and\u002For radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;\n* Karnofsky functional score of ≥ 60;\n* Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:\n\n  * Straining more than 25% of defecations.\n  * Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.\n  * Sensation of incomplete evacuation more than one-fourth (25%) of defecations.\n  * Sensation of anorectal obstruction\u002Fblockage more than one-fourth (25%) of defecations.\n  * Manual maneuvers to facilitate more than one-fourth (25%) of defecations.\n  * Fewer than three spontaneous bowel movements per week.\n  * Loose stools are rarely present without the use of laxatives.\n  * Insufficient criteria for irritable bowel syndrome.\n* Patient should be able to understand and complete all study assessments on their own\n* Patient should be able to understand and provide signed informed consent in English.\n\nTable 3. Rome IV criteria for functional constipation FUNCTIONAL CONSTIPATION Diagnostic criteria\\*\n\n1. Must include two or more of the following:\\*\\*\n2. Straining during more than ¼ (25%) of defecations\n3. Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations\n4. Sensation of incomplete evacuation more than ¼ (25%) of defecations\n5. Sensation of anorectal obstruction\u002Fblockage more than ¼ (25%) of defecations\n6. Fewer than three SBM per week\n7. Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)\n\n9\\. Loose stools are rarely present without the use of laxatives 9. Insufficient criteria for irritable bowel syndrome Note \\*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis\n\nExclusion Criteria:\n\n* Patients who have allergic history to herbs or Chinese medicine;\n* Clinically significant abnormal liver (2 times the ULN for ALT or AST) and kidney disfunction(eGFR below 59 mL\u002Fmin\u002F1.73m² ) from recent laboratory test recorded in the medical record (within 2 month);\n* Patients who have any signs of bowel obstruction, or have high risk of bowel obstruction assessed by their treating physician, including factors such as tumor invasion into abdominal organs, recent abdominal surgery, and prior abdominal radiation therapy;\n* Patients who are prescribed opioid antagonists including methylnaltrexone, naloxegol and naldemedine for opioid induced constipation and required not to stop the medication;\n* Women who are pregnant, lactating, or not practicing proper contraception by patient report.Patient's should follow proper contraception guidelines for at least 30 days following last dose of the study drug.",{"count":74,"type":21},70,[24],"The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with placebo, a pill that looks like MZRW and is given in the same way, but contains no medication. The researchers will also study the effect MZRW has on the gut microbiome. The gut microbiome is a diverse community of microorganisms living in the digestive system, essential for digestion and immune function.",[78,79,27],"Constipation","Cancer",[81,82,83,84,85,86],"constipation","functional constipation","Ma-Zi-Ren-Wan","MZRW","25-076","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-05-20",{"date":90,"type":32},"2026-05-22",{"date":92,"type":32},"2025-07-15",{"date":94,"type":21},"2028-07-15",{"name":86,"class":39},7,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":49,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100634208","co-supplementation-with-bifidobacterium-longum-w11-and-colopectin-for-maintenance-therapy-in-children-with-functional-constipation-100634208","NCT07536698","Co-supplementation With Bifidobacterium Longum W11 and Colopectin for Maintenance Therapy in Children With Functional Constipation","Efficacy of Co-supplementation With Bifidobacterium Longum W11 and Colopectin in the Maintenance Therapy of Children With Functional Constipation: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Children aged 2 to 6 years\n* Diagnosis of functional constipation\n* Receiving maintenance therapy with macrogol for at least 3 months\n* Candidates for weaning from macrogol therapy\n\nExclusion Criteria:\n\n* Children with intestinal meteorism or flatulence\n* Children diagnosed with organic constipation\n* History of previous abdominal surgery\n* Children with frailty or disabilities\n* Presence of other organ diseases or syndromes","2 Years","6 Years",{"count":107,"type":21},100,[24],"Functional constipation is a common condition in children and often requires prolonged maintenance treatment with macrogol. This randomized, double-blind, placebo-controlled trial will evaluate whether co-supplementation with Bifidobacterium longum W11 and Colopectin can support maintenance therapy in children with functional constipation who are receiving macrogol and are candidates for weaning. Participants aged 2 to 6 years will be randomized to receive either the active supplementation or placebo once daily for 4 weeks, followed by 4 weeks of follow-up after treatment discontinuation. The study will assess persistence of constipation after macrogol discontinuation, as well as stool consistency, distress during evacuation, soiling episodes, and treatment compliance.",[27],"2026-04-15",{"date":113,"type":32},"2026-04-17",{"date":115,"type":21},"2026-04-20",{"date":117,"type":21},"2027-05-17",{"name":119,"class":39},"Liaquat University of Medical & Health Sciences",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":48,"sex":49,"minAge":127,"maxAge":17,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":40},"100543594","the-efficacy-and-palatability-of-developed-polyethylene-glycol-based-formula-for-children-with-functional-constipation-100543594","NCT06357897","The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation","Faculty of Medicine, Chulalongkorn University","Inclusion Criteria:\n\nChildren will be enrolled in this study when they meet 2 criteria:\n\n* Age from 6 months to 18 years old\n* Children are diagnosed with FC according to ROME IV criteria\n\nExclusion Criteria:\n\nChildren will be excluded from the study if they meet any of the following criteria:\n\n* Having an organic cause of constipation such as anorectal malformations, Hirschsprung disease, myelomeningocele, hypothyroidism, etc.\n* Suspected GI obstruction\n* Receiving medication affecting bowel movement\n* Having a history of allergy to PEG and stevia.","6 Months",{"count":129,"type":21},52,[24],"This study aims to evaluate the efficacy and palatability of a developed polyethylene glycol-based formula compared with the standard polyethylene glycol (PEG) in the treatment of children with functional constipation for 8 weeks. Besides, we also aim to assess the side effects of a developed PEG-based formula as well as evaluate the change of rectal diameter from baseline at each visit between 2 groups.",[27],[134,135,136,137],"Functional constipation","Children","Polyethylene glycol","Palatability","2026-03-27",{"date":140,"type":32},"2026-04-02",{"date":142,"type":32},"2024-05-03",{"date":144,"type":21},"2026-12",{"name":146,"class":39},"Chulalongkorn University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":49,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":40},"100604366","bioamicus-complete-for-functional-gastrointestinal-symptoms-in-infants-aged-0-to-24-months-100604366","NCT07148583","BioAmicus Complete for Functional Gastrointestinal Symptoms in Infants Aged 0 to 24 Months","Evaluation of the Efficacy and Safety of the Multistrain Probiotic \"BioAmicus Complete\" in Improving Gastrointestinal Symptoms in Children Aged 0-24 Months: A Randomized, Open-Label, Parallel-Group, Controlled Trial","CTBE2503","Inclusion Criteria:\n\n* Age 0-24 months at enrollment.\n* Infant has clinician-assessed functional gastrointestinal symptoms (e.g., colic\u002Firritability, regurgitation, constipation, loose stools), judged suitable for study participation.\n* Parent or legal guardian provides written informed consent and agrees to comply with study procedures (questionnaires\u002Fdiaries and sample collection, if applicable).\n* Caregivers agree to avoid other probiotic products during the study period, except as directed by the study team.\n\nExclusion Criteria:\n\n* Major congenital gastrointestinal anomalies or known chronic gastrointestinal diseases requiring ongoing prescription therapy (e.g., Hirschsprung disease, inflammatory bowel disease, short-bowel syndrome).\n* Clinically unstable condition or severe\u002Fcritical illness that could interfere with participation or safety in the opinion of the investigator.\n* Known or suspected primary or secondary immunodeficiency, or current immunosuppressive therapy.\n* History of severe allergy or hypersensitivity to components of the investigational product.\n* Recent use of systemic antibiotics within 14 days prior to baseline, or use of probiotic supplements within 14 days prior to baseline (per protocol).\n* Participation in another interventional clinical trial within 30 days prior to enrollment or during the study.\n* Any condition that, in the investigator's judgment, would make the participant unsuitable for the study or confound outcome assessments.","0 Days","24 Months",{"count":158,"type":21},110,[24],"Infants often experience functional gastrointestinal symptoms (e.g., colic, excessive gas, regurgitation, constipation, or loose stools) that distress families and may reflect an imbalance of the gut microbiome. This study evaluates whether the multistrain probiotic BioAmicus Complete can improve caregiver-reported gastrointestinal symptoms in infants 0-24 months and is safe for use in this population.\n\nThe primary assessment is the change in the Infant Gastrointestinal Symptom Questionnaire (IGSQ) total score from the start to the end of the study period. Secondary assessments include symptom domains (colic\u002Fregurgitation, stool frequency and consistency), caregiver quality of life, growth parameters (weight and length), health care utilization and antibiotic exposure, and overall safety\u002Ftolerability (adverse events and serious adverse events). Stool samples will be analyzed to explore changes in the gut microbiome.",[162,163,27,164,165],"Infantile Colic","Gastroesophageal Reflux (GER)","Functional Diarrhea","Dysbiosis",[167,168,169,170,171,172,173,174],"BioAmicus Complete","probiotic","multistrain probiotic","infant","functional gastrointestinal symptoms","Infant Gastrointestinal Symptom Questionnaire","gut microbiome","stool microbiome","2026-01-28",{"date":177,"type":32},"2026-01-29",{"date":179,"type":32},"2025-09-05",{"date":181,"type":21},"2026-05-30",{"name":183,"class":39},"Haiphong University of Medicine and Pharmacy",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":194,"studyType":195,"phases":4,"briefSummary":196,"conditions":197,"keywords":203,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":40},"100432993","functional-digestive-disorders-observatory-100432993","NCT04918329","Functional Digestive Disorders Observatory","Observatory of Functionnal Digestive Disorders","OTFI","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Patients with functional digestive disorder for more of 3 months;\n* Patients assessed as part of routine care;\n* Patients affiliated to the Social Security ;\n* Patients not opposed to participation in the Centre\n\nExclusion Criteria:\n\n* Person deprived of liberty by administrative or judicial decision or major protected subject (under guardianship or curatorship);\n* Patients unable for any reason to read, understand, respond questionnaires (visual, psychiatric, cognitive, etc.)",{"count":193,"type":21},2000,"10 Years","OBSERVATIONAL","Functional digestive pathologies are defined by symptoms such as functional dyspepsia, gastroesophageal reflux, irritable bowel syndrome, gastroesophageal reflux, functional constipation, functional diarrhea, functional bloating, the opioid-induced constipation and fecal incontinence, without organic substratum. These diseases are very common in the general population (20%) and represent the first cause of consultation in city gastroenterology. The pathophysiology of these functional disorders is complex and often multifactorial: disturbances in digestive motility, altered visceral sensitivity, sphincter dysfunction, post-surgery, intestinal inflammation, dysbiosis, and impairment of the gut-brain axis. For example, it has been shown that one in four patients with inflammatory bowel disease in confirmed remission report digestive symptoms consistent with a functional bowel disorder, suggesting a possible pathophysiological continuum between these two conditions.\n\nThe objective of this study is to collect prospective clinical and tests data and a biological collection from biological samples (digestive biopsies, blood, urine and fecal samples) collected as part of the standard care. This collection could identify diagnostic or prognostic markers of the therapeutic response.",[198,199,27,200,201,202],"Irritable Bowel Syndrome","Dyspepsia","Faecal Incontinence","Abdominal Pain (AP)","Vomiting Syndrome",[204,205],"Observatory","functional digestive disorders","2026-01-05",{"date":208,"type":32},"2026-01-08",{"date":210,"type":32},"2020-10-09",{"date":212,"type":21},"2030-10-09",{"name":214,"class":39},"University Hospital, Rouen",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":247},"100404550","phase-3-efficacy-of-conservative-treatment-of-functional-defecatory-disorders-in-females-with-pelvic-organ-prolapse-100404550","NCT04547816","Efficacy of Conservative Treatment of Functional Defecatory Disorders in Females With Pelvic Organ Prolapse","Evaluation of Complex (Physical Therapy and Diet) Treatment of Functional Defecatory Disorders in Females With Pelvic Organ Prolapse","Inclusion Criteria:\n\n* Willingness to participate (signed informed consent form)\n* Females with rectocele I-II grade or rectocele I-II grade and internal rectal invagination and functional defecatory disorders (per Rome IV guidelines) confirmed on the basis of complex examination including high-resolution anorectal manometry\n\nExclusion Criteria:\n\n* rectocele III grade;\n* internal genitals prolapse;\n* history of abdominal or pelvic surgery that may impact bowel motility (excluding non-complicated appendectomy or laparoscopic cholecystectomy);\n* gynecological surgery that may influence sensory or reservoir function of rectum;\n* history of major cardiovascular events, or presence of current conditions that in case of participation of the patient in the study may put her at risk of exacerbation or complication;\n* start of any new concomitant medication with mechanisms of action that influence rectal motility, sensory function, muscle tone and\u002For contractility\n* inability to understand and\u002For follow the instructions to perform all the procedures required per protocol\n* general condition of the patient that make her ineligible by the discretion of the investigator","70 Years",{"count":107,"type":21},[225],"PHASE3","This study is planned to evaluate the efficacy of complex conservative treatment (including tibial neuromodulation, biofeedback therapy, special pelvic floor training and diet modification) in women with pelvic organ prolapse",[228,27,229],"Pelvic Floor Prolapse","Rectocele",[231,232,233,234,235,236,237],"pelvic floor prolapse","conservative treatment","functional disorders of defecation","rectocele","diet modification","biofeedback therapy","tibial neuromodulation","2025-08-01",{"date":240,"type":32},"2025-08-03",{"date":242,"type":32},"2020-07-01",{"date":244,"type":21},"2026-05-31",{"name":246,"class":39},"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology",2,{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":222,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":40},"100576479","nutriplant---opportunities-for-increasing-consumption-of-local-fruits-and-vegetables-100576479","NCT06785831","NutriPlant - Opportunities for Increasing Consumption of Local Fruits and Vegetables","Opportunities for Increasing Consumption of Local Fruits and Vegetables in Slovenian Population (NutriPlant)","NutriPlant","1. Inclusion criteria:\n\n   * Signed informed consent of the participant to participate in the study\n   * Age between 18 and 70 years\n   * Functional constipation or irritable bowel syndrome\n   * Expressed willingness to eat the investigated food daily (sauerkraut, apples, dried apples or psyllium; period of four weeks)\n2. Exclusion criteria:\n\n   * Known allergy to the investigated foods (fresh apples, dried apples, sauerkraut or psyllium)\n   * Pregnancy or breastfeeding\n   * Previous gastrointestinal surgery with the exception of cholecystectomy and appendectomy\n   * Other gastrointestinal diseases (chronic inflammatory bowel disease, celiac disease, gastroparesis, etc.)\n   * Serious chronic diseases\n   * Introduction of extensive changes in diet or physical activity in the last 4 weeks before the inclusion examination\n   * Regular use of laxatives or inability to stop using laxatives for the duration of the study\n   * Concurrent participation in another study",{"count":257,"type":21},120,[24],"The effects of different foods to normal bowel function in adult population will be investigated. A randomised controlled intervention trial will be conducted on about 120 (30 per group) adult (18-70 years) subjects with functional constipation and irritable bowel syndrome with constipation according to the IV. Rome criteria. At least one week before inclusion in the study, patients will stop taking laxatives and other anti-constipation medications. Subjects will be randomly selected to consume one of the test foods (fresh apples, dried apples, sauerkraut) or the active control (psyllium) in the equivalent amount of 3 g of fiber per day for 4 weeks. Subjects will be asked not to change their lifestyle habits, such as diet and physical activity level, and not to take oral laxatives during the period of participation in the study.",[27,198],"2025-01-14",{"date":263,"type":32},"2025-01-21",{"date":265,"type":21},"2025-01-20",{"date":267,"type":21},"2026-09-30",{"name":269,"class":39},"Institute of Nutrition, Slovenia (Nutris)",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":49,"minAge":276,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":40},"100557198","a-single-arm-pilot-study-of-the-chinese-herbal-medicine-formula-scd-2101-for-the-functional-constipation-in-the-elderly-100557198","NCT06534996","A Single Arm Pilot Study of the Chinese Herbal Medicine Formula (SCD-2101) for the Functional Constipation in the Elderly","Inclusion Criteria:\n\n* (1) Age ≥ 60 years old (2) Meet the Rome IV diagnostic criteria for functional constipation (3) Complete spontaneous bowel movements ≤ 2 times per week, to be assessed based on a 2-week electronic diary record (CSBMs are defined as the number of times within a 24-hour period that the patient can defecate spontaneously without the use of laxatives or enemas and feels that the stool is completely evacuated) (4) Have colonoscopy results with a diagnosis of no significant abnormalities seen or no more than 3 colorectal polyps, each less than 0.5 cm in size (based on results within the last 5 years before screening) (5) Understand and be able to follow written and oral instructions in Chinese (6) Capable of independently using WhatsApp and an electronic diary, and completing a 2-week electronic diary record during the screening period (7) The subject is informed and voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n* (1) Secondary constipation (constipation caused by drugs or other diseases); (2) Currently using or requiring continued use of medications that may affect the outcomes of the trial (including but not limited to: antibiotics, hormonal drugs, analgesics, neurotransmitter drugs, gut flora-regulating medications, etc.); (3) Colonoscopy or sigmoidoscopy reveals clinically significant abnormalities; (4) Clinically significant abnormalities in laboratory tests or imaging examinations within the last 6 months; (5) History of allergy to traditional Chinese medicine; (6) History of abdominal surgery within the past year (except for laparoscopic appendectomy); (7) Patients with psychiatric diseases or those requiring the use of psychotropic drugs; (8) Deemed by the researchers as unsuitable to participate in this study for psychological or physical reasons.","60 Years",{"count":278,"type":21},14,[24],"This single-arm, open-label pilot clinical trial will test the hypothesis that SCD-2101, a Chinese herbal medicine formula, will have efficacy in alleviating constipation in elderly individuals with functional constipation. All participants (n=14) will receive 2 weeks of intervention and 2 weeks of follow-up.",[27],[283],"elderly, Chinese Herbal Medicine, Functional Constipation","2024-08-19",{"date":286,"type":32},"2024-08-20",{"date":288,"type":32},"2024-08-01",{"date":290,"type":21},"2024-11-30",{"name":292,"class":39},"Hong Kong Baptist University"]